What Is the Treatment for Goodpasture Syndrome?
Clinical Scenario
Goodpasture syndrome is driven by a pathogenic anti-GBM autoantibody. This protocol addresses standard first-line management, with treatment designed to rapidly suppress circulating anti-GBM antibody levels while controlling the inflammatory process.
Treatment Approach — Partial Overview
Standard treatment combines plasmapheresis — to rapidly clear the pathogenic anti-GBM autoantibody from circulation — with immunosuppressive agents that inhibit further autoantibody production and ameliorate inflammation. The complete protocol specifies which agents are used, how each is sequenced and adjusted, and how dosing is modified for renal function and patient age.
Primary Treatment Goal
Anti-GBM antibody levels fully suppressed within 14 days of initiating plasma exchange.
References
DOI: 10.55563/clinexprheumatol/tep3k5
- The therapy is based on plasmapheresis, which rapidly remove the pathogenic autoantibody, together with corticosteroids and cyclophosphamide, which inhibit autoantibody production and ameliorate inflammation.
- Continue until antibody levels are fully suppressed or for 14 d